Evidence map›Paper›PMID 28336905›Full record

ArticleNanomaterials (Basel, Switzerland)2017

A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging.

Silvia Giordano, Valentina Pifferi, Lavinia Morosi, Melinda Morelli, Luigi Falciola, Giuseppe Cappelletti, Sonja Visentin, Simonetta A Licandro, Roberta Frapolli, Massimo Zucchetti and 4 more

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Silvia GiordanoEnvironmental Health Sciences Department, Mass Spectrometry Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. silvia.giordano@marionegri.it.
Valentina PifferiDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy. valentina.pifferi@unimi.it.
Lavinia MorosiOncology Department, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. lavinia.morosi@marionegri.it.
Melinda MorelliDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy. melinda.morelli@unimi.it.
Luigi FalciolaDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy. luigi.falciola@unimi.it.
Giuseppe CappellettiDipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy. giuseppe.cappelletti@unimi.it.
Sonja VisentinDepartment of Molecular Biotechnology and Health Science, University of Torino, Via Nizza 52, 10126 Torino, Italy. sonja.visentin@unito.it.
Simonetta A LicandroOncology Department, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. simonettaandrea.licandro@marionegri.it.
Roberta FrapolliOncology Department, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. roberta.frapolli@marionegri.it.
Massimo ZucchettiOncology Department, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. massimo.zucchetti@marionegri.it.
Roberta PastorelliEnvironmental Health Sciences Department, Mass Spectrometry Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. roberta.pastorelli@marionegri.it.
Laura BrunelliEnvironmental Health Sciences Department, Mass Spectrometry Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. laura.brunelli@marionegri.it.
Maurizio D'IncalciOncology Department, Cancer Pharmacology Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. maurizio.dincalci@marionegri.it.
Enrico DavoliEnvironmental Health Sciences Department, Mass Spectrometry Laboratory, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Via La Masa 19, 20156 Milano, Italy. enrico.davoli@marionegri.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The imaging of drugs inside tissues is pivotal in oncology to assess whether a drug reaches all cells in an adequate enough concentration to eradicate the tumor. Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging (MALDI-MSI) is one of the most promising imaging techniques that enables the simultaneous visualization of multiple compounds inside tissues. The choice of a suitable matrix constitutes a critical aspect during the development of a MALDI-MSI protocol since the matrix ionization efficiency changes depending on the analyte structure and its physico-chemical properties. The objective of this study is the improvement of the MALDI-MSI technique in the field of pharmacology; developing specifically designed nanostructured surfaces that allow the imaging of different drugs with high sensitivity and reproducibility. Among several nanomaterials, we tested the behavior of gold and titanium nanoparticles, and halloysites and carbon nanotubes as possible matrices. All nanomaterials were firstly screened by co-spotting them with drugs on a MALDI plate, evaluating the drug signal intensity and the signal-to-noise ratio. The best performing matrices were tested on control tumor slices, and were spotted with drugs to check the ion suppression effect of the biological matrix. Finally; the best nanomaterials were employed in a preliminary drug distribution study inside tumors from treated mice.

Indexed as

cancer imaginggold nanoparticleshalloysiteMALDImass spectrometry imagingTiO2

Identifiers

PMID28336905
PMCPMC5388173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.